Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

May 31, 2009

Conditions
Keloid
Interventions
DRUG

Avotermin

"10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure."

Trial Locations (1)

63141

Body Aesthetic Plastic Surgery and Skincare Center, St Louis

All Listed Sponsors
lead

Renovo

INDUSTRY

NCT00469235 - Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars | Biotech Hunter | Biotech Hunter